Barinthus Biotherapeutics
BRNS | NASDAQ
$0.74
-$0.02 (-2.50%)
At close: Sep 8, 2026, 4:00 PM ET
Barinthus Biotherapeutics Company Profile
Company profile explainedCompany Profile
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Key Executives
| Name | Position |
|---|---|
| William J. Enright | Chief Executive Officer & Director |
| Douglas J. Swirsky | CFO & Principal Accounting Officer |
| Leon Hooftman | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | 15-12G | Filing |
| Sep 14, 2026 | EFFECT | Filing |
| Sep 11, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 11, 2026 | 4/A | [Amend] Filing |
| Sep 09, 2026 | 25 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
Barinthus Biotherapeutics
| Country | United States |
| IPO Date | Apr 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | William James Enright |
Contact Details
20400 Century Boulevard Germantown,
Maryland 20874 United States
Stock Details
| Ticker Symbol | BRNS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828185 |
| CUSIP Number | 91864C107 |
| ISIN Number | US91864C1071 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove BRNS